LDL-Cholesterol Does Not Predict Heart Risk Among Heart Patients

New Diagnostic Test, CERT, Improves Risk Prediction Over Standard Laboratory Tests

Espoo, Finland, June 24, 2019 - New international study shows that LDL-cholesterol is unable to predict future cardiovascular events and fails to identify those coronary heart disease patients who are at the highest risk and who would benefit most from additional attention and preventive action.

Cardiovascular diseases are the leading cause of death worldwide. In 2015, coronary heart disease affected 110 million people and resulted in 8.9 million deaths. Common belief is that coronary heart disease (CHD) patients are at an equally high risk for cardiovascular events such as heart attack. The newly published study showed that there is a substantial variability in the risk of future cardiovascular events in CHD patients.

” It is common to assume that all CHD patients have an equivalent cardiovascular risk, but according to this study this seems not to be the case. For instance, the 10-year cardiovascular death risk of a CHD patient may vary from 5% to over 20%.”, says Reijo Laaksonen, Chief Medical Officer for Zora Biosciences.

The high-risk patients are not well identified with current clinical markers. For instance, widely used LDL-cholesterol was not able to identify those CHD patients who were at the highest risk of cardiovascular death or myocardial infarction.

Cardiovascular diseases take a heavy toll on the healthcare systems and the economy. It is fair to assume that the high-risk patients are main drivers of this high cost. Cardiovascular diseases are mostly preventable. Therefore, more accurate identification of persons at the highest risk and directing preventive actions and resources to those, could help in reducing health care costs, morbidity and mortality.

A Finnish diagnostic company, Zora Biosciences Oy, has developed a diagnostic test, CERT (Cardiovascular Event Risk Test) that identifies the risk of heart attack more accurately than LDL-cholesterol or LDL-cholesterol based measurements. CERT enables patient stratification into risk groups more accurately than the currently used lipid tests, and provides an enhanced tool for capturing the risk. CERT, and its latest version CERT2, is a blood test that measures ceramide lipids by mass spectrometry. Plasma ceramides represent the next generation of clinical predictors for adverse cardiovascular events resulting from unstable atherosclerotic plaques. Ceramides are bioactive lipids that play a central role in cell membrane integrity, cellular stress response, inflammation, and cell death.

Laboratory tests such as CERT2 may offer an advantage over classical risk calculators in terms of their reliability, ease of use and predictive power. Therefore, for those willing to invest in prevention, CERT2 provides an efficient tool for focusing resources where most appropriate, namely, the CHD high-risk patients.

The research is published in the highest ranking cardiovascular journal, the European Heart Journal (https://doi.org/10.1093/eurheartj/ehz387), a 10 000 coronary heart disease (CHD) patient study showing the prognostic performance of CERT in comparison to standard laboratory measurements.


About CERT
CERT is a blood sample test that measures the risk of cardiovascular events and the risk of type 2 diabetes. CERT has been extensively validated in more than 80,000 patient samples analyzed retrospectively and shown to be a much more reliable predictor of cardiovascular risk than other markers in use today. CERT, the ceramide-based risk score test is available widely in Finland through private health care providers and select public sites, branded as “Hertta” in Europe., all samples being analyzed by the Zora reference facility. CERT is also commercialized as a Laboratory Developed Test (LDT) in the USA, in which Zora collaborated with Mayo Clinic. For more information about CERT, visit the website www.hertta.fi/en or www.zora.fi

About Zora
Zora Biosciences Oy (“Zora”; www.zora.fi) a diagnostics discovery company uses mass spectrometry to search for biomarker signals in clinical studies. Zora develops lipid biomarkers into analytically validated high throughput clinical diagnostic assays. Zora has exclusive intellectual property protecting its molecular diagnostic tests of cardiovascular risk. For more information about Zora Biosciences please visit the website: www.zora.fi

Contact:

Zora Biosciences Oy

email: info@zora.fi

tel. +358 40 833 3018

Back to news